SelectQuote Valuation
Is SLQT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SLQT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SLQT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SLQT's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SLQT?
Key metric: As SLQT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is SLQT's PS Ratio? | |
|---|---|
| PS Ratio | 0.3x |
| Sales | US$1.38b |
| Market Cap | US$432.19m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | 12.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does SLQT's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
CRD.B Crawford | 0.4x | 6.1% | US$555.6m |
WDH Waterdrop | 1.1x | 9.9% | US$420.6m |
HIPO Hippo Holdings | 2.1x | 17.6% | US$708.9m |
GOCO GoHealth | 0.2x | 8.0% | US$257.5m |
SLQT SelectQuote | 0.3x | 10.5% | US$432.2m |
Price-To-Sales vs Peers: SLQT is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1x).
Price to Sales Ratio vs Industry
How does SLQT's PS Ratio compare vs other companies in the US Insurance Industry?
Price-To-Sales vs Industry: SLQT is good value based on its Price-To-Sales Ratio (0.3x) compared to the US Insurance industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is SLQT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.3x |
| Fair PS Ratio | 0.9x |
Price-To-Sales vs Fair Ratio: SLQT is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$2.55 | US$4.50 +76.5% | 9.1% | US$5.00 | US$4.00 | n/a | 3 |
| Nov ’25 | US$2.04 | US$4.50 +120.6% | 9.1% | US$5.00 | US$4.00 | n/a | 3 |
| Oct ’25 | US$2.02 | US$4.50 +122.8% | 9.1% | US$5.00 | US$4.00 | n/a | 3 |
| Sep ’25 | US$4.08 | US$4.50 +10.3% | 11.1% | US$5.00 | US$4.00 | n/a | 2 |
| Aug ’25 | US$4.01 | US$4.50 +12.2% | 11.1% | US$5.00 | US$4.00 | n/a | 2 |
| Jul ’25 | US$3.06 | US$4.50 +47.1% | 11.1% | US$5.00 | US$4.00 | n/a | 2 |
| Jun ’25 | US$3.12 | US$4.50 +44.2% | 11.1% | US$5.00 | US$4.00 | n/a | 2 |
| May ’25 | US$1.61 | US$4.00 +148.4% | 25.0% | US$5.00 | US$3.00 | n/a | 2 |
| Apr ’25 | US$2.00 | US$4.00 +100.0% | 25.0% | US$5.00 | US$3.00 | n/a | 2 |
| Mar ’25 | US$2.01 | US$4.00 +99.0% | 25.0% | US$5.00 | US$3.00 | n/a | 2 |
| Sep ’24 | US$1.24 | US$2.38 +91.5% | 26.3% | US$3.00 | US$1.75 | US$4.08 | 2 |
| Aug ’24 | US$1.92 | US$2.58 +34.5% | 22.8% | US$3.00 | US$1.75 | US$4.01 | 3 |
| Jul ’24 | US$1.95 | US$2.58 +32.5% | 22.8% | US$3.00 | US$1.75 | US$3.06 | 3 |
| Jun ’24 | US$1.58 | US$2.58 +63.5% | 22.8% | US$3.00 | US$1.75 | US$3.12 | 3 |
| May ’24 | US$1.16 | US$2.42 +108.3% | 34.1% | US$3.00 | US$1.25 | US$1.61 | 3 |
| Apr ’24 | US$2.17 | US$2.50 +15.2% | 28.3% | US$3.00 | US$1.50 | US$2.00 | 3 |
| Mar ’24 | US$2.49 | US$2.50 +0.4% | 28.3% | US$3.00 | US$1.50 | US$2.01 | 3 |
| Feb ’24 | US$0.85 | US$1.27 +49.2% | 41.4% | US$2.00 | US$0.80 | US$1.11 | 3 |
| Jan ’24 | US$0.67 | US$1.27 +88.5% | 41.4% | US$2.00 | US$0.80 | US$1.37 | 3 |
| Dec ’23 | US$0.71 | US$1.27 +78.2% | 41.4% | US$2.00 | US$0.80 | US$1.33 | 3 |
| Nov ’23 | US$0.69 | US$1.69 +144.9% | 19.2% | US$2.00 | US$1.25 | US$1.38 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Fidelis Insurance Holdings
US$2.2b
A specialty insurer, provides insurance and reinsurance solutions in Bermuda, the Republic of Ireland, and the United Kingdom.
FIHL
US$19.90
7D
-0.2%
1Y
62.1%
Markel Group
US$21.5b
A diverse holding company, engages in marketing and underwriting specialty insurance products in the United States, Bermuda, the United Kingdom, and Germany.
MKL
US$1,694.12
7D
2.3%
1Y
18.5%
China Life Insurance
HK$1.1t
Operates as a life insurance company in the People’s Republic of China.
CILJ.F
HK$2.00
7D
-0.6%
1Y
46.0%